Search research articles
Contact Us
Filters
Showing results (91-100 of 338) with videos related to
Page
of 34
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication
Kathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Melanoma Management
|
September 8, 2018
Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for <i>BRAF</i>-mutant melanoma: a case report
Samantha L Kass, Allison F Linden, Patrick G Jackson, et al.
Future Oncology (London, England)
|
April 20, 2022
Real-world treatment patterns and overall survival in <i>BRAF</i>-mutant melanoma patients treated with immunotherapy or targeted therapy
Michael B Atkins, Cristina Julian, Matthew H Secrest, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients
Samuel J Klempner, Toni K Choueiri, Eric Yee, et al.
The Journal of Investigative Dermatology
|
March 11, 2011
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study
Clara Curiel-Lewandrowski, Tamar Nijsten, Maria L Gomez, et al.
Melanoma Research
|
September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma
Amy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Archives of Internal Medicine
|
September 14, 2011
Prospective evaluation of analgesic use and risk of renal cell cancer
Eunyoung Cho, Gary Curhan, Susan E Hankinson, et al.
Journal for Immunotherapy of Cancer
|
December 14, 2020
Strategies for improving the management of immune-related adverse events
Aung Naing, Joud Hajjar, James L Gulley, et al.
BMC Cancer
|
October 19, 2017
Societal preferences for adjuvant melanoma health states: UK and Australia
Mark R Middleton, Michael B Atkins, Kaitlan Amos, et al.
Page
of 34
Search research articles
Search
Showing results (91-100 of 338) with videos related to
Sort By:
Page
of 34
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 12, 2013
Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication
Kathleen M Mahoney, Allison Ackerman, Daniel C Cho, et al.
Melanoma Management
|
September 8, 2018
Bowel perforation associated with robust response to BRAF/MEK inhibitor therapy for <i>BRAF</i>-mutant melanoma: a case report
Samantha L Kass, Allison F Linden, Patrick G Jackson, et al.
Future Oncology (London, England)
|
April 20, 2022
Real-world treatment patterns and overall survival in <i>BRAF</i>-mutant melanoma patients treated with immunotherapy or targeted therapy
Michael B Atkins, Cristina Julian, Matthew H Secrest, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 18, 2012
Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients
Samuel J Klempner, Toni K Choueiri, Eric Yee, et al.
The Journal of Investigative Dermatology
|
March 11, 2011
Long-term use of nonsteroidal anti-inflammatory drugs decreases the risk of cutaneous melanoma: results of a United States case-control study
Clara Curiel-Lewandrowski, Tamar Nijsten, Maria L Gomez, et al.
Melanoma Research
|
September 9, 2010
Impact of concomitant immunosuppression on the presentation and prognosis of patients with melanoma
Amy Frankenthaler, Ryan J Sullivan, Wei Wang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
May 1, 2016
Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG)
Christopher J Anker, Kenneth F Grossmann, Michael B Atkins, et al.
Archives of Internal Medicine
|
September 14, 2011
Prospective evaluation of analgesic use and risk of renal cell cancer
Eunyoung Cho, Gary Curhan, Susan E Hankinson, et al.
Journal for Immunotherapy of Cancer
|
December 14, 2020
Strategies for improving the management of immune-related adverse events
Aung Naing, Joud Hajjar, James L Gulley, et al.
BMC Cancer
|
October 19, 2017
Societal preferences for adjuvant melanoma health states: UK and Australia
Mark R Middleton, Michael B Atkins, Kaitlan Amos, et al.
Page
of 34